Observational studyInfection2026
Respiratory syncytial virus in adults aged ≥ 50 years in France: a database and time-series modelling analysis (2014-2020).
Observational study in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to quantify the burden of respiratory syncytial virus (RSV)- and influenza-attributed acute respiratory infections (ARI) in older adults in France. Modelling was applied to real-world data on ARI-attributed hospital admissions and in-hospital mortality to estimate pathogen-specific outcomes and investigate the underreporting of RSV in standard clinical practice. Additionally, healthcare resource utilisation was assessed.
methodsThis retrospective, observational cohort study used routinely collected, secondary care data from the Programme National de Médicalisation des Systèmes d'Information (PMSI) database. All patients aged ≥ 50 years with an ARI-related hospitalisation, identified through International Classification of Diseases, 10th Revision (ICD-10) coding, between July 2014 and February 2020 were included. The predicted number and annual rate of hospitalisations were calculated using a Quasi-Poisson regression model, stratified by age group. Sensitivity analyses were used to investigate cardiorespiratory hospital admissions and in-hospital mortality.
results2,009,218 patients with an ARI-related hospitalisation were identified. Predicted rates of RSV- and influenza-attributable ARI hospitalisations ranged from 0.05 and 0.27 per 1000 person-years among 50-54-year-olds to 14.38 and 12.48 per 1000 person-years among ≥ 90-year-olds, respectively. Rates of in-hospital mortality were similar between the two pathogens, while RSV was predicted to account for a much larger number of cardiorespiratory hospitalisations than influenza. RSV-coded hospitalisations lasted 8-11 days across age groups, and 25.6% of 55-59-year-olds hospitalised with RSV were admitted to an intensive care unit.
conclusionThese data reveal a substantial burden of RSV-related morbidity and mortality among older adults in France, demonstrating a need to prioritise RSV prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.